Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course preoperative radiotherapy plus cadonilimab and chemotherapy in locally advanced rectal cancer
ChiCTR2300075658Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in rectal adenocarcinoma, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Pathological complete response rate. Started Jul 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300075658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075658.